Monoclonal antibodies for brain tumour treatment
- 1 September 2004
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 4 (9), 1453-1471
- https://doi.org/10.1517/14712598.4.9.1453
Abstract
Conventional treatment of brain tumours includes surgical, radiotherapeutic and chemotherapeutic modalities. Nonetheless, the outcome of patients with brain tumours, in particular glioblastoma, remains poor. Immunotherapy with armed or unarmed monoclonal antibodies targeting tumour-specific antigens has emerged in the last two decades as a novel potential adjuvant treatment for all types of neoplasia. Many challenges to its implementation as a safe and viable therapy for brain tumours still need to be addressed; nevertheless, results from ongoing Phase I/II clinical trials are encouraging, as disease stabilisation and patient survival prolongation have been observed. Advances in preclinical and clinical research indicate that treatment of brain tumours with monoclonal antibodies can be increasingly adjusted to the characteristics of the targeted tumour and its environment. This aspect relies on the careful selection of the target antigen and corresponding specific monoclonal antibody, and antibody format (size, class, affinity), conjugation to the appropriate toxin or radioactive isotope (half-life, range), and proper compartmental administration.Keywords
This publication has 78 references indexed in Scilit:
- Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptorProceedings of the National Academy of Sciences of the United States of America, 2003
- Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant GliomasJournal of Clinical Oncology, 2002
- Unarmed, tumor-specific monoclonal antibody effectively treats brain tumorsProceedings of the National Academy of Sciences, 2000
- Identification of a Glioblastoma-Associated Tenascin-C Isoform by a High Affinity Recombinant AntibodyThe American Journal of Pathology, 1999
- Tumor antigens in astrocytic gliomasGlia, 1995
- Tenascin expression in human glioma cell lines and normal tissuesJournal of Neuroimmunology, 1992
- Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin [published erratum appears in J Cell Biol 1992 Feb;116(3):833]The Journal of cell biology, 1991
- Relationship between gene amplification and chromosomal deviations in malignant human gliomasCancer Genetics and Cytogenetics, 1987
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975